Optimized Method of G-Protein-Coupled Receptor Homology Modeling: Its Application to the Discovery of Novel CXCR7 Ligands

  • Yasushi Yoshikawa
    Drug Discovery Department, Research & Development Division, PharmaDesign Inc., 2-19-8 Hatchobori, Chuo-ku, Tokyo 104-0032, Japan
  • Shinya Oishi
    Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
  • Tatsuhiko Kubo
    Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
  • Noriko Tanahara
    Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
  • Nobutaka Fujii
    Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
  • Toshio Furuya
    Drug Discovery Department, Research & Development Division, PharmaDesign Inc., 2-19-8 Hatchobori, Chuo-ku, Tokyo 104-0032, Japan

書誌事項

公開日
2013-05-29
資源種別
journal article
DOI
  • 10.1021/jm400307y
公開者
American Chemical Society (ACS)

この論文をさがす

説明

Homology modeling of G-protein-coupled seven-transmembrane receptors (GPCRs) remains a challenge despite the increasing number of released GPCR crystal structures. This challenge can be attributed to the low sequence identity and structural diversity of the ligand-binding pocket of GPCRs. We have developed an optimized GPCR structure modeling method based on multiple GPCR crystal structures. This method was designed to be applicable to distantly related receptors of known structural templates. CXC chemokine receptor (CXCR7) is a potential drug target for cancer chemotherapy. Homology modeling, docking, and virtual screening for CXCR7 were carried out using our method. The predicted docking poses of the known antagonists were different from the crystal structure of human CXCR4 with the small-molecule antagonist IT1t. Furthermore, 21 novel CXCR7 ligands with IC50 values of 1.29-11.4 μM with various scaffolds were identified by structure-based virtual screening.

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (61)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ